Clonmel Healthcare is delighted to announce the launch of Bosutinib Clonmel 100mg, 500mg film-coated tablets.
Bosutinib Clonmel is indicated for the treatment of adult patients with;
- Newly diagnosed chronic phase (CP) Philadelphia chromosome -positive myelogenous leukaemia (PH+CML)
- CP, accelerated phase (AP), and blast phase (BP) Ph +CML previously treated with one or more tyrosine kinase inhibitor(s) [TKI(s)] and for whom imatinib, nilotinib and dasatinib are not considered appropriate treatment options
Full prescribing information is available on request or alternatively please go to www.clonmel-health.ie. Medicinal product subject to restricted medical prescription.
Please contact Clonmel Healthcare on 01-6204000 if you require any additional information.
PA 126/369/1-3. PA Holder: Clonmel Healthcare Ltd., Clonmel, Co. Tipperary. Date prepared: October 2024. 2024/ADV/BOS/259H
Read our Latest News Here
Read October IPN Here
